This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bijl, M Articles by Kallenberg, C G. Search for Related Content PubMed PubMed Citation Articles by Bijl, M Articles by Kallenberg, C G. Social Bookmarking                         What's this?

Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activity

Department of Internal Medicine, Division of Clinical Immunology, University Hospital, PO Box 30.001, 9700 RB Groningen, The Netherlands m.bijl{at}int.azg.nl

G Horst

P C Limburg

Department of Pathology and Laboratory Medicine, University Hospital, Groningen, The Netherlands

C GM Kallenberg

Department of Internal Medicine, Division of Clinical Immunology, University Hospital, Groningen, The Netherlands

Levels of apoptotic lymphocytes have been found to be increased in SLE and persistence of apoptotic cells has been associated with autoantibody production. Increased lymphocyte Fas (CD95) expression due to lymphocyte activation may account for increased susceptibility to Fasmediated apoptosis in SLE.

Flowcytometry was performed to evaluate membrane expression of Fas in combination with the activation markers CD25, HLA-DR and CD38 on, respectively, CD4⁺, CD8⁺ and CD19⁺ lymphocytes of SLE patients with inactive (n = 20) and with active disease (n = 13). SLEDAI-scores were calculated. Healthy volunteers (n = 14) served as controls.

Percentages of CD4⁺ T-cells expressing CD25 and CD19⁺ B-cells expressing CD38 were increased in patients with active disease compared to controls (P = 0.03, P = 0.04, respectively). In contrast to CD4⁺ and CD8⁺ cells, percentages of CD19⁺ cells expressing Fas were increased in SLE patients with active disease (P = 0.0002 vs controls). In these patients percentages of cells double positive for both CD38 and Fas were increased compared to patients with inactive disease (P = 0.006) and controls (P = 0.0007). Percentages of CD19⁺ cells expressing Fas correlated with SLEDAI-scores.

In SLE patients, percentages of Fas-expressing B-lymphocytes are increased, are related to the state of lymphocyte activation, and correlate to disease activity. Increased Fas expression results in a higher susceptibility for Fas-mediated apoptosis, which might contribute to the increased levels of apoptoticlymphocytes in SLE patients.

Key Words: SLE • Fas • CD95 • lymphocyte activation • apoptosis

Lupus, Vol. 10, No. 12, 866-872 (2001)
DOI: 10.1191/096120301701548517


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Z. Dai, C. J. Turtle, G. C. Booth, S. R. Riddell, T. A. Gooley, A. M. Stevens, T. Spies, and V. Groh Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus J. Exp. Med., April 13, 2009; 206(4): 793 - 805. [Abstract] [Full Text] [PDF]

				M De La Torre, J. Urra, and J Blanco Raised expression of cytokine receptor gp130 subunit on peripheral lymphocytes of patients with active lupus. A useful tool for monitoring the disease activity? Lupus, March 1, 2009; 18(3): 216 - 222. [Abstract] [PDF]

				A Hostmann, A. Jacobi, H Mei, F Hiepe, and T Dorner Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus Lupus, December 1, 2008; 17(12): 1064 - 1069. [Abstract] [PDF]

				M N Lub-de Hooge, E G E de Vries, S de Jong, and M Bijl Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus Ann Rheum Dis, June 1, 2005; 64(6): 854 - 858. [Abstract] [Full Text] [PDF]

				S. Akilesh, D. J. Shaffer, and D. Roopenian Customized Molecular Phenotyping by Quantitative Gene Expression and Pattern Recognition Analysis Genome Res., July 1, 2003; 13(7): 1719 - 1727. [Abstract] [Full Text] [PDF]

				J W. Dieker, J van der Vlag, and J H. Berden Triggers for anti-chromatin autoantibody production in SLE Lupus, December 1, 2002; 11(12): 856 - 864. [Abstract] [PDF]